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Abstract: The human electrophysiological and pharmacological
properties of XEN-D0101 were evaluated to assess its usefulness for
treating atrial ﬁbrillation (AF). XEN-D0101 inhibited Kv1.5 with an
IC50 of 241 nM and is selective over non-target cardiac ion channels
(IC50 Kv4.3, 4.2 mM; hERG, 13 mM; activated Nav1.5, .100 mM;
inactivated Nav1.5, 34 mM; Kir3.1/3.4, 17 mM; Kir2.1,..100 mM).
In atrial myocytes from patients in sinus rhythm (SR) and chronic AF,
XEN-D0101 inhibited non-inactivating outward currents (Ilate) with
IC50 of 410 and 280 nM, respectively, and peak outward currents
(Ipeak) with IC50 of 806 and 240 nM, respectively. Whereas Ilate is
mainly composed of IKur, Ipeak consists of IKur and Ito. Therefore, the
effects on Ito alone were estimated from a double-pulse protocol where
IKur was inactivated (3.5 mM IC50 in SR and 1 mM in AF). Thus,
inhibition of Ipeak is because of IKur reduction and not Ito. XEN-D0101
signiﬁcantly prolonged the atrial action potential duration at 20%,
50%, and 90% of repolarization (AF tissue only) and signiﬁcantly
elevated the atrial action potential plateau phase and increased con-
tractility (SR and AF tissues) while having no effect on human ven-
tricular action potentials. In healthy volunteers, XEN-D0101 did not
signiﬁcantly increase baseline- and placebo-adjusted QTc up to a max-
imum oral dose of 300 mg. XEN-D0101 is a Kv1.5/IKur inhibitor with
an attractive atrial-selective proﬁle.
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INTRODUCTION
Atrial ﬁbrillation (AF) contributes to overall cardiovas-
cular morbidity and mortality and occurs in 1%–2% of the
general population. Patients with AF have a 5-fold increased
risk for stroke, and approximately one-ﬁfth of all strokes can
be attributed to AF.1
AF can be triggered by ectopic activity, single circuit
reentry, or multiple circuit reentry.2 Current strategies to
control AF involve either sinus rhythm (SR) maintenance
or heart rate control. AF termination and SR maintenance
can be achieved by inhibiting K+ channels responsible for
atrial repolarization. Although SR control may be the pre-
ferred and most effective treatment of AF, none of the SR
control drugs currently available are able to maintain SR
without signiﬁcant side effect risk.3 Furthermore, the cur-
rently used class 3 antiarrhythmic agents lack atrial speciﬁc-
ity, producing highly undesirable proarrhythmic liability in
the ventricles that can lead to torsade de pointes and sudden
cardiac death.4 Thus, there is a clear unmet medical need for
new pharmacological AF therapies with improved efﬁcacy
and safety.5
A putative atrial-selective drug target is Kv1.5, which
underlies the cardiac ultrarapidly activating outward potas-
sium current (IKur) in humans
6–9 and importantly displays
atrial-speciﬁc expression.10–12 Inhibition of IKur extends the
repolarization phase of the atrial cardiac action potential in
AF patients13 to provide desirable antiarrhythmic effects with-
out unfavorably affecting the ventricles. Selective Kv1.5/IKur
inhibitors thus represent a potentially safer pharmacological
intervention strategy.14 In addition to antiarrhythmic proper-
ties, Kv1.5/IKur inhibitors may also improve atrial contractility
and thereby reduce thromboembolic risk.15
Herein we report that XEN-D0101 alters action poten-
tials recorded from human atrial tissue, but not human
ventricular tissue, and that this is because of the selective
Kv1.5/IKur modulation and possibly Kv4.3/Ito modulation at
higher test concentrations. These observations reinforce the
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notion that selective Kv1.5/IKur inhibitors represent a new
class of atrial-selective antiarrhythmic agents.
METHODS
For in vitro studies, stock solutions of XEN-D0101
(a thienopyrimidine) formulated in dimethylsulfoxide
(DMSO) were frozen and stored as aliquots at approximately
2208C until use. Serial dilution of stock solutions in DMSO
were performed in glass vials before dilution in experimental
solution to achieve the desired ﬁnal perfusion concentrations,
with a vehicle concentration of typically 0.1% vol/vol
DMSO.
Studies reported here conform to the principles outlined
in the Declaration of Helsinki were reviewed and approved by
relevant Ethics Committees, and human subjects gave written
informed consent. Atrial trabecular muscle from the right atrium
appendage was received from SR and AF patients undergoing
open heart surgery for coronary artery or valve disease (ethical
no. 15.1/01031/006/2008 and EK790799). Human ventricular
tissue was obtained from general organ donors whose hearts
were explanted to obtain pulmonary and aortic valves for
transplantation (ethical no. 339/PI/10, 4991-0/2010-1018EKU).
Preparations from patients previously receiving antiarrhythmic
drugs were excluded. Additional donor information is provided
in Supplemental Digital Content 3 (see Supplementary Meth-
ods, http://links.lww.com/JCVP/A107).
Cloned Cardiac Ion Channel
Electrophysiology (Performed by Xention)
Cell lines stably expressing human Kv1.5, Kv4.3, or
Nav1.5 in CHO cells and hERG, Kir3.1/3.4, or Kir2.1 in
HEK293 cells were maintained in media containing 10% fetal
calf serum and appropriate selection antibiotic. Cells were
grown either in suspension or in T-ﬂasks and routinely
passaged. Cells for patch clamping experiments were plated
onto glass cover slips before use. Cells for automated patch
clamping experiments (Nav1.5) were freshly prepared on
each experimental day. Standard gigaseal whole-cell patch
clamp techniques were performed at room temperature using
glass pipettes (2–4 MV). Experimental solutions are given in
Supplemental Digital Content 3 (see SupplementaryMethods,
http://links.lww.com/JCVP/A107). Patch clamp ampliﬁer (EPC)
and Pulse software from HEKA Electronics (Chester, Nova
Scotia, Canada) were used. Series resistance was compen-
sated by greater than 70%. Standard voltage protocols for
Kv1.5 (VHold 280 mV, 0 mV/900 ms, 240 mV/100 ms,
0.2 Hz), Kv4.3 (VHold 280 mV, +60 mV/1 s, 0.1 Hz),
Kir2.1 (VHold 260 mV, 2110 mV/400 ms, 0.2 Hz), Kir3.1/
3.4 (VHold 280 mV, 2140 mV/100 ms, ramp +60 mV/500
ms, 280 mV, 0.1 Hz), and hERG (VHold 280 mV, +20 mV/5
s, 240 mV/5 s, 0.067 Hz) were employed. For Nav1.5, a 4-
pulse voltage clamp protocol was used to elicit current after
whole-cell access was achieved using a QPatch16. From
a holding potential of 290 mV, an initial test pulse to 210
mV (10 ms) was applied to elicit an inward Na+ current (P1).
Further test pulses to 210 mV (all 10 ms duration) were
applied after conditioning steps to either 290 mV (P2) for
500 ms to relieve channel inactivation or 5 seconds to 270
mV to promote inactivation (P3). Finally, the membrane was
repolarized back to290 mV for 100 ms before a ﬁnal test pulse
to210 mV was delivered to measure recovery from inactivated
block (P4). The command voltage was applied every 15 sec-
onds. After a stabilization period, a cumulative concentration
response experiment was performed. Peak amplitude of the
inward Nav1.5 current of P2 and P3 was measured at the end
of each drug application period.
Isolation of Myocytes and Recording of Ipeak
and Ilate Outward Currents From SR and AF
Human Atrial Tissue at 378C (Performed by
Dresden University of Technology)
See Supplemental Digital Content 3 (see Supplementary
Methods, http://links.lww.com/JCVP/A107) for atrial myocyte
isolation procedures. Experiments were performed at physio-
logical temperature (378C). Myocytes held at 260 mV were
subject to a double-pulse protocol (0.2 Hz) to +50 mV (500 ms
each) separated by an intermediate 25 ms step to 260 mV.
Peak outward currents (Ipeak) of the ﬁrst test pulse were ana-
lyzed to determine mixed effects on Ito and IKur. Late outward
current mainly represented effects on slowly inactivating IKur.
The area under the curve of the initial 50 ms of the second
clamp step is a measure of charge transfer and was analyzed as
indicator of Ito.
In Vitro Human Action Potential Studies at
378C (Performed by Dresden University of
Technology and University of Szeged)
Tissue preparations were stimulated at 1 Hz with a 2-ms
square wave stimulus. Measured parameters were resting
membrane potential (RMP), action potential amplitude
(APA), action potential duration at 20%, 50%, 75%, and
90% repolarization (APD20, APD50, APD75, and APD90),
maximum depolarization rate, dV/dtmax, conduction time
(ct), and “plateau potential” (PLT) deﬁned as the mean mem-
brane potential between 20% and 30% of APD (PLT20).
In Vitro Human Atrial Contractility Studies
(Performed by Dresden University
of Technology)
The study included 14 preparations from 8 patients in SR
group, and 9 preparations came from 5 patients with chronic
AF. Preparations had a mean length 4.66 0.3 mm and a diam-
eter of 1.4 6 0.1 mm (n = 23). Resting tension of each prep-
aration was adjusted to yield half maximum active force
development. The trabeculae were mounted in an organ bath
that contained 50 mL of oxygenated Tyrodes solution circulat-
ing via the gas stream. The composition of the bath solution
was 126.7 mM NaCl, 0.42 mM NaH2PO4, 22 mM NaHCO3,
5.4 mM KCl, 1.8 mM CaCl2, and 1.5 mM MgCl2, pH 7.4,
when equilibrated with 5% CO2 in O2 at 37 6 0.38C.
The preparations were stimulated regularly at a frequency of
1 Hz. After a stabilization period of 60–90 minutes, XEN-
D0101 was added in cumulatively increasing concentrations
allowing at least 15 minutes for the effect to develop before
the next increment in concentration. At the end of each
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experiment, the preparations were exposed to 8 mM CaCl2 for
assessment of maximum force development.
QTc Evaluation in Healthy Volunteers
(Performed by Xention)
A double-blind, randomized, placebo-controlled phase
1 study was performed to determine safety and tolerability of
XEN-D0101 and to carefully examine the drug plasma
concentration–QTc relationship. Healthy male volunteers
were recruited into the study, and volunteers were speciﬁcally
excluded if they had a clinically signiﬁcant electrocardio-
graphic (ECG) abnormality, cardiac arrhythmia, heart dis-
ease, hypokalemia, hyperkalemia, structural heart disease,
bradycardia, myocardial channelopathy, or mean QTc (Fri-
dericia correction) greater than 450 ms. Subjects remained
resident in the Clinical Pharmacology Unit throughout the
study period. Six groups of 8 subjects (fasted overnight) took
a single dose of XEN-D0101 or placebo. At each dose level, 6
subjects were randomized to receive active treatment and 2
subjects received placebo. Dosages investigated were 15, 30,
45, 75, 150, and 300 mg XEN-D0101. Blood samples for
assay of XEN-D0101 were taken before and frequently up
to 48 hours after each single dose. Assay of plasma
concentrations of XEN-D0101 was performed using a high-
performance liquid chromatography, tandem mass spectros-
copy method. The lower limit of quantiﬁcation for the assay
was 0.5 ng/mL. Safety ECG telemetry (1-lead ECG) was
monitored continuously from dosing until 24 hours afterward,
using a SpaceLabs system to monitor heart function and
detect proarrhythmic events in real time. To accurately detect
drug-related changes in the QTc interval, continuous 12-lead
ECGs were recorded using SEER MC recorders (GE Health-
care) with Mason–Likar electrodes. A continuous 12-lead
ECG was recorded for 14 hours, starting at 1 hour before
dosing and ﬁnishing at 13 hours after dosing (and at corre-
sponding times on Day 1). Recordings were also made on
Day 2 (23237 hours after dosing). ECG analysis was per-
formed on approximately 30,000 ECGs using a semiautomatic
method with sufﬁcient precision and reproducibility as
described elsewhere.16 As ECGs were measured automati-
cally, 20% of the measured ECGs were selected (either ran-
domly or targeting the extreme QT- and RR-interval (QT,
RR) measurements of each participant) and reviewed by an
experienced and medically qualiﬁed observer. The QT inter-
val was corrected for heart rate using individual regression
equations. In each subject, the regression model that provided
FIGURE 1. Effect of a range of con-
centrations of XEN-D0101 on cloned
cardiac ion channel expressed in
mammalian cells. A, Representative
steady state Kv1.5 current traces in
control and after exposure to XEN-
D0101. Current inhibition at the end
of the depolarizing step to 0 mV was
77% for this cell. B, Kv4.3 current
traces in the absence and presence
of 3 mM XEN-D0101. Peak Kv4.3
current inhibition for the cell shown
was 43.7%. C, Mean Kv1.5 and
Kv4.3 current inhibition (6SEM)
data are shown plotted as a function
of XEN-D0101 concentration and
fitted with a sigmoidal function
(constrained at 0% and 100%)
yielding a Kv1.5 IC50 of 241 nM
[95% confidence interval (CI), 152–
383 nM, n = 6–12 cells at each
concentration] and a Hill coefficient
(nH) of 1.3 6 0.2 and a Kv4.3 IC50
of 4.2 mM (95% CI, 2.8–6.4 mM,
n = 5 cells at each concentration, P,
0.0001, 2-tailed t test, cf. Kv1.5) and
nH of 0.6 6 0.1. D, Mean current inhibition by XEN-D0101 is plotted as a function of concentration and fitted with a sigmoidal
function (constrained at 0% and 100%) to yield a hERG IC50 of 13 mM (95% CI, 11.3–15.1 mM, n = 4–6 cells at each concen
tration, P , 0.0001, 2-tailed t test, cf. Kv1.5) and an nH of 1.3 6 0.2. Effect of XEN-D0101 on Nav1.5 current was evaluated on
the QPatch16 using a 4-pulse protocol described in the Methods. Mean Nav1.5 current inhibition data are shown plotted as
a function of XEN-D0101 concentration yielding IC50 values for Peak 3 (Nav1.5 inactivated-state block): 34.4 mM (95% CI,
21.9–53.9 mM, P , 0.0001, 2-tailed t test, cf. Kv1.5) and nH of 1.4 6 0.2 and Peak 2 (Nav1.5 activated-state block): .100 mM
(n = 6 cells). Mean inhibition data for Kir3.1/3.4 are shown plotted as a function of XEN-D0101 concentration yielding IC50 value
of 17 mM (95% CI, 12–24 mM, n = 4–6 cells, P, 0.0001, 2-tailed t test, cf. Kv1.5) and an nH of 0.76 0.1. Mean inhibition data for
Kir2.1 are shown plotted as a function of XEN-D0101, nominal inhibition of current was observed over a range of concentrations
up to 100 mM, and no meaningful fit to these data was possible. Kv1.5 fit data are shown as a dashed line for comparison.
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the lowest regression residuals was converted into an individ-
ualized heart rate correction, which yielded a QT corrected
for heart rate (QTc). The means of the repeated measurements
on Day 1 were used to derive time-matched changes from
baseline (ΔQTc). The subjects who received placebo in indi-
vidual cohorts were pooled (n = 12), and their time-matched
DQTc readings on days 1 and 2 were averaged at each time
point to obtain a DQTc placebo proﬁle of the study. The on-
treatment DQTc proﬁles were corrected for placebo to obtain
DDQTc proﬁles for each treatment group.
Statistical Analysis
Data are typically presented as mean 6 SEM, and
where appropriate, 95% conﬁdence intervals are given.
Student t test or 1-way analysis of variance (ANOVA) with
multiple measurements were used as appropriate. Differences
were considered statistically signiﬁcant for *P , 0.05, §P ,
0.01, and #P , 0.001. Concentration effect modeling was
performed for QTc evaluation in healthy volunteers with
ΔΔQTc intervals being regressed onto the plasma concentra-
tions of XEN-D0101 at the exact times when the continuous
12-lead ECGs were recorded. The effect of XEN-D0101
plasma concentration on ΔΔQTc was investigated using
a regression model and ANOVA. At each time of stable
supine rest, XEN-D0101 plasma concentration was interpo-
lated using nonparametric superposition (see Figure 1, Supple-
mental Digital Content 1, http://links.lww.com/JCVP/A105).
A mixed-effects model, which included plasma concentration,
FIGURE 2. Effect of a range of con-
centrations of XEN-D0101 on Ipeak,
Ilate, and Ito currents recorded from
human atrial myocytes from SR and
AF donors at 378C. A and B, Original
current recordings, control and in
the presence of 10 mM XEN-D0101,
from SR and AF are shown. Double-
pulse protocol—holding potential:
260 mV, 2 voltage steps to +50 mV,
duration 500 ms, intermediate pulse
to 260 mV, duration 25 ms (see
inset in B). Effects on Ito were quan-
tified by the area under the curve
(AUC) of the inactivating current of
the second pulse (inset in A). C and
D, Concentration-dependent effects
of XEN-D0101 on peak current
(Ipeak) and late current (Ilate) in SR
and AF are shown. Dashed lines
represent adapted Hill equations
assuming a Hill slope of 1 to the
mean data with IC50 values for SR of
806 nM [562–1152 nM, 95% confi-
dence interval (CI)] and 413 nM
(308–554 nM, 95% CI) for Ipeak and
Ilate, respectively, and for AF 241 nM
(136–429 nM, 95% CI) and 281 nM
(112–708 nM, 95% CI) for Ipeak and
Ilate, respectively. E and F, Concen-
tration-dependent effects of XEN-
D0101 on Ito measured as AUC (in
pC/pF) of inactivating current com-
ponent during the initial 50 ms of
second voltage step (see inset in A)
for SR and AF are shown. Two alter-
native curve adaptations were con-
ducted assuming the maximum
value = mean control, Hill coefficient
= 1, and either (1) a minimum
value of 0.03 pC/pF or (2) full block
(0 pC/pF). The respective IC50 values
were 3.5 mM (2.4–5.1 mM, CI) and
8.3 mM (4.3–16.2 mM, CI). For AF,
the IC50 was 1.0 mM (0.56–1.9 mM,
CI). n = numbers (cells per patients).
Mean data 6 SEM.
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treatment group, and interaction between plasma concentration
and treatment group, as ﬁxed factors, and subject as a random
factor, was evaluated.
RESULTS
Effect of XEN-D0101 on Cloned Cardiac
Ionic Channels
The pharmacological proﬁle of XEN-D0101 against
several ion channels known to be expressed and functionally
important in the human heart is reported in Figure 1 (original
current traces are shown in Figure 2, Supplemental Digital
Content 2, http://links.lww.com/JCVP/A106). XEN-D0101
inhibited Kv1.5 (241 nM IC50) and was shown to be 17-fold
selective over Kv4.3, greater than 50-fold selective over
hERG, greater than 70-fold selective over Kir3.1/3.4, and
greater than 100-fold selective over Nav1.5 and Kir2.1.
Although only observed at very high test concentrations,
XEN-D0101 preferentially blocked inactivated-Nav1.5 over
open-Nav1.5 channels.
Effect of XEN-D0101 on Ipeak and Ilate Currents
Recorded From Human Atrial Myocytes
At physiological temperature, XEN-D0101’s ability to
inhibit Ipeak (peak outward currents = Ito and IKur) and Ilate (late
outward currents = slowly inactivating IKur and other unchar-
acterized currents, also called Isus in previous studies
6) was
determined in human atrial myocytes from SR and AF donors.
Additionally, the charge carried during the fast inactivating
current component of the second voltage step (Fig. 2A, inset)
was used as surrogate to estimate the effect on Ito (mainly
conducted by Kv4.3). XEN-D0101 concentration dependently
reduced all current components, although with different
sub-micromolar potencies in both SR and AF atrial myocytes
(Fig. 2). In SR, the IC50 for Ipeak was approximately 4-fold
greater than the corresponding value in AF. Inhibition of Ilate,
largely representing noninactivating IKur, is similar in SR and
AF tissues (Figs. 2C, D). Inhibition of Ito based on area under
the curve/charge of the inactivating peak current during the
second voltage step is pronounced in SR but small and per-
haps not biologically relevant in AF because of reduced
contributions of Ito in AF (Figs. 2E, F). The IC50 selectivity
ratio of Ilate over Ito in SR tissue calculates between 8- and
20-fold depending on the assumption for IC50 determination
(Fig. 2E).
Effect of XEN-D0101 on Human Cardiac
Action Potentials
Effects on human atrial and ventricular action potentials
are shown in Figure 3 and Table 1. The most striking
concentration-dependent effects of 1 and 3 mM XEN-D0101
in AF atrial trabeculae were robust elevation in plateau poten-
tial (.16 mV) and prolongation in APD20 (.47 ms), APD50
(.47 ms), and APD90 (.30 ms). In SR atrial trabeculae,
XEN-D0101 also signiﬁcantly elevated the plateau potential
(.26 mV) but in contrast to AF preparations signiﬁcantly
reduced APD90 (,84 ms). Resting potential became signiﬁ-
cantly less negative (by 3 mV) in SR atrial tissue. All effects
were at least partially reversible upon drug washout with the
exception of APD90 shortening in SR tissue. Action potential
amplitude, dV/dtmax, and conduction time were not altered.
XEN-D0101 up to 3 mM did not signiﬁcantly alter any action
potential parameter in human ventricular tissue. Consistent with
what has been reported elsewhere in the literature under control
conditions, the resting membrane potential of SR and AF atrial
cells was more depolarized than observed in ventricular cells
and SR atrial cells were more depolarized than AF atrial cells.17
FIGURE 3. Effects of XEN-D0101 on cardiac action potentials. Example of individual tracings recorded in the presence of
increasing concentrations of XEN-D0101 shown at the end of the exposure period of 20 minutes. The effects of XEN-D0101
on human action potentials were examined in right atrial trabeculae from patients in SR and AF and human ventricle at 1 Hz.
The compound concentration dependently elevated the plateau phase of the action potential in atrial tissue only. In SR, this
effect was associated with shortening of APD90, whereas prolongation of APD90 was observed in AF. XEN-D0101 did not
change action potential parameters recorded from human ventricular tissue. AP measurements and number (n) are provided in
Table 1.
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Effect of XEN-D0101 on Human Atrial
Tissue Contractility
In human SR atrial tissue, XEN-D0101 signiﬁcantly
increased contractility at 3 mM (.30%) and 10 mM (.38%)
but only at 10 mM (.63%) in human AF atrial tissue. The
force of contraction was greater in the presence of both XEN-
D0101 and 3 mM 4-action potential compared with XEN-
D0101 alone, but this did not match the maximum force of
contraction observed in the presence of 8 mM Ca2+. These
results are reported in Figure 4.
Effect of XEN-D0101 on QTc Interval and
Drug-induced Proarrhythmia in Healthy
Human Subjects
Comprehensive ECG recordings and ECG analysis were
performed in a phase 1 clinical trial to determine whether
XEN-D0101 prolongs the QTc interval in human. The quality
of the ECG data from this study was high with 90% of subjects
having a regression residual below 6 ms. XEN-D0101 plasma
concentration plotted against ΔΔQTc is given in Figure 5, and
most notably, XEN-D0101 plasma concentrations exceeded
3000 ng/mL (;10 mM drug concentration), in some volunteers
without increasing ΔΔQTc. The regression coefﬁcients for
plasma concentration versus ΔΔQTc derived from the mixed-
effects model were not signiﬁcantly different from zero (P =
0.1990). The ANOVA analysis of the individual model com-
ponents showed that XEN-D0101 plasma concentration did not
signiﬁcantly affect ΔΔQTc (P = 0.6719). Categorical analysis
of QT and QTc was performed, and no subjects on active
treatment had a QT or QTc greater than 450 ms or increase
in QTc from baseline greater than 30 ms. In addition to 12-lead
Holter monitoring, single-lead ECG telemetry monitoring was
performed continually throughout the clinical trial. All results
of ECG telemetry were considered by the investigator to be
normal. There were no clinically signiﬁcant changes, including
induction of AF or ventricular proarrhythmia after XEN-D0101
dosing.
TABLE 1. Effect of XEN-D0101 on Action Potentials Recorded From Human Atrial and Ventricular Tissues at 1 Hz
Effect of XEN-D0101 on action potentials recorded from AF human atrial trabecular muscle (n = 6)
Parameter Control 0.3 mM 1 mM 3 mM Wash
RMP (mV) 277 6 1§ 277 6 1 277 6 1 276 6 1 277 6 0
APA (mV) 100 6 3§ 102 6 3 102 6 3 103 6 3 102 6 3
APD20 (ms) 40 6 8§ 40 6 8 59 6 7# 87 6 5# 32 6 10
APD50 (ms) 106 6 9* 108 6 9 127 6 8§ 153 6 6# 108 6 12
APD90 (ms) 202 6 8# 204 6 8 213 6 9 232 6 8# 210 6 12
dV/dtmax (V/s) 180 6 27 181 6 37 181 6 45 175 6 45 173 6 36
ct (ms) 5 6 1 5 6 1 5 6 1 5 6 1 5 6 1
PLT20 (mV) 2 6 3§ 3 6 3 11 6 3§ 18 6 2# 23 6 4
Effect of XEN-D0101 on action potentials recorded from SR human atrial trabecular muscle (n = 6)
Parameter Control 0.3 mM 1 mM 3 mM Wash
RMP (mV) 272 6 1 271 6 1 271 6 1 269 6 1* 269 6 1
APA (mV) 91 6 1 93 6 2 93 6 2 95 6 2 91 6 2
APD20 (ms) 6 6 0 6 6 1 10 6 2 58 6 16§ 6 6 1
APD50 (ms) 153 6 13 148 6 11 134 6 14 148 6 13 107 6 25
APD90 (ms) 337 6 12 319 6 16 282 6 17* 253 6 14# 258 6 29#
dV/dtmax (V/s) 145 6 10 156 6 15 149 6 6 145 6 4 137 6 7
ct (ms) 4 6 0 4 6 0 4 6 0 4 6 0 4 6 0
PLT20 (mV) 216 6 2 214 6 2 210 6 2 10 6 5# 218 6 3
Effect of XEN-D0101 on action potentials recorded from human ventricular tissue (n = 6–8)
Control 1 mM Control 3 mM
RMP (mV) 287 6 1 288 6 1 287 6 1 286 6 1
APA (mV) 106 6 2 108 6 2 108 6 3 110 6 2
APD25 (ms) 147 6 10 145 6 10 131 6 15 140 6 15
APD50 (ms) 208 6 15 210 6 16 188 6 13 198 6 16
APD90 (ms) 273 6 21 277 6 23 249 6 12 257 6 14
dV/dtmax (V/s) 249 6 36 245 6 64 292 6 49 255 6 33
XEN-D0101 concentration dependently elevated the plateau phase of the action potential in SR and AF atrial trabecular muscle. In SR, this effect was associated with shortening of
APD90, whereas prolongation of APD50 and APD90 was observed in AF. XEN-D0101 signiﬁcantly increased the RMP by 3 mV in SR atrial trabecular muscle. Multiple measures
ANOVA with Bonferroni postcomparison test was used for statistical analysis of drug effects versus control values for each AP parameter. Student t test was used to compare control
action potential parameters in SR and AF.
*P , 0.05, §P , 0.01, #P , 0.001.
APA, action potential amplitude; ct, conduction time.
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DISCUSSION
Ion channel electrophysiology studies performed
against native and cloned cardiac ion channels demonstrated
that XEN-D0101 preferentially targets Kv1.5/Ilate (ie, IKur)
with moderate selectivity over Kv4.3/Ito (between 8- and
20-fold). XEN-D0101 is selective for Kv1.5 over hERG
(.50-fold), Kir3.1/3.4 (.70-fold), and Nav1.5 and Kir2.1
(.100-fold). Inhibition of Ilate was demonstrated in both
SR and AF atrial tissues, whereas Ito was signiﬁcantly down-
regulated in AF atrial tissue and therefore difﬁcult to measure.
Comparing recent studies on IKur remodeling in AF, down-
regulation of IKur is less pronounced than that of Ito.
13 Also in
this investigation, the late component of outward current is
not signiﬁcantly different from SR. There are indications that
besides IKur, other currents may contribute to the late
current.13
Findings reported here for human cardiac action potential
studies are consistent with the ion channel pharmacology of
XEN-D0101. Action potential recordings were performed with
atrial tissue from patients who either were in SR or had
a history of chronic AF for at least 6 months duration. Action
potentials from patients in SR showed a characteristic spike and
dome conﬁguration, whereas those from patients in AF had
a triangulated shape.18 The triangular shape of action potentials
from AF preparations is the result of electrical remodeling
driven by altered ion channel expression and regulation.19 In
this study, XEN-D0101 evoked changes similar to previously
reported effects of 4-AP, which at concentrations selective for
IKur block elevated the plateau potential in SR and AF prepa-
rations and signiﬁcantly shortened APD90 in SR but prolonged
APD90 in AF trabecula.
18 However, in the presence of XEN-
D0101, the reduction in APD90 in SR tissue was not reversible
in the washout period, unlike plateau elevation in SR and AF
tissues and APD90 increase in AF tissue, suggesting that
this effect may not be drug related. A possible explanation
for this is that Ca2+ current rundown is occurring in SR tissue,
and this effect is absent or much smaller in AF tissue because
ICa is already downregulated. The concentrations of XEN-
D0101 required to change action potential parameters were 1
and 3 mM, which is higher than the Kv1.5/Ilate IC50 value. The
reason for this difference could relate to drug accessibility to
the Kv1.5 channels being much greater in single dissociated
myocytes compared with large multicellular preparations, per-
haps because of permeability/diffusion problems. Bioanalysis
to measure XEN-D0101 levels in cardiac tissue was not per-
formed to conﬁrm this hypothesis. Additionally, because the
action potential is a multichannel event, the effect that a con-
ductance change in a single-channel type has on the overall
shape of the action potential depends on the relative contribu-
tion to the momentary overall sum of conductances. Similar
differences in potencies on current and action potential param-
eters are regularly observed. Data from recombinant Kir2.1 and
Kir3.1/3.4 channels suggest that the small depolarization in
resting membrane potential observed in SR tissue, which is
unlikely to be biologically relevant, is not because of inhibition
of native IK1 or IKACh.
XEN-D0101 increased contractile force in human SR
and AF atrial trabeculae in a concentration-dependent man-
ner. Similarly, elevation of the plateau phase of the human
atrial action potential by 4-AP or via the nonselective IKur and
Ito blocker AVE0118 leads to a concentration-dependent pos-
itive inotropic effect.15,18 The increase in force of contraction
after elevation of the plateau phase has been explained by an
indirect enhancement of Ca2+ inﬂux via voltage-dependent
L-type Ca2+ channels18 or via Na+–Ca2+ exchanger operating
in its reverse mode.20 AF is associated with marked contrac-
tile dysfunction that can be partially counteracted by 4-AP;
however, as demonstrated here, the positive inotropic effect is
less robust than in SR. The positive inotropic effects of XEN-
D0101 at 10 mM are unlikely to be because of only Kv1.5/Ilate
inhibition due to lack of positive inotropic effects at 1 mM,
FIGURE 4. Effects of XEN-D0101 on atrial tissue contractility.
Effects of XEN-D0101 and 3 mM 4-AP in addition to XEN-
D0101 on force of contraction of isolated human right atrial
trabeculae from patients in SR (black symbols) and AF (red
symbols). At the end of each experiment, 8 mM CaCl2 (+Ca)
was added for the assessment of maximum force of contrac-
tion. C, pre-drug control. n = Number of trabeculae/number
of patients. *P , 0.05, §P , 0.01, #P , 0.001 versus pre-drug
control.
FIGURE 5. XEN-D0101 plasma concentration plotted against
baseline- and placebo-adjusted QTc (ΔΔQTc) values derived
from healthy volunteers (n = 63). Concentration effect mod-
eling showed no evidence of a consistent relationship between
plasma concentration of XEN-D0101 and ΔΔQTc in healthy
volunteers orally dosed with XEN-D0101.
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which is known to signiﬁcantly alter atrial action potential
parameters and selectively inhibit Kv1.5/Ilate.
The absence of XEN-D0101–induced QTc prolonga-
tion and proarrhythmia in healthy volunteers in the clinical
study referenced herein is an important safety milestone that
has not previously been reported for selective Kv1.5 drugs.
Indeed, it has previously been reported that a “loss of func-
tion” KCNA5 polymorphism may induce susceptibility to AF
in human, although in vivo causality was not demonstrated in
this study.21 The ability of XEN-D0101 to induce AF was
carefully evaluated in this clinical trial with continuous ECG
monitoring, and no incidents of atrial tachycardia or AF were
reported. The lack of drug-induced QTc prolongation in
healthy volunteers is consistent with the human ventricular
action potential recordings performed in the presence of
XEN-D0101. However, it remains to be determined whether
the same safety conclusions can be made with respect to the
AF patient population, who often experience electrical and
structural remodeling in the heart because of cardiovascular
disease and ageing. The total drug plasma concentrations in
some of the healthy volunteers in the phase 1 clinical study
reached ;10 mM (1 mM unbound drug concentration), a con-
centration that maximally modulates Kv1.5.
CONCLUSIONS
Studies reported herein demonstrate that XEN-D0101 is
selective for Kv1.5/Ilate over nontarget cardiac ion channels
and in accordance with these pharmacological properties
selectively inﬂuences various action potential and contractility
parameters in human atrial AF tissue but not human ventric-
ular tissue. It remains to be demonstrated that these atrial ex
vivo ﬁndings translate to atrial-selective antiarrhythmic prop-
erties in AF patients.
STUDY LIMITATIONS
It has to be admitted that the number of tissue samples
from patients is relatively low. The variability of electrophys-
iological parameters in human ex vivo preparations is on the
other hand large. Because AF preparations contract much less
than SR preparations, action potentials are generally more
stable in the AF group. Studying Ca2+ handling is beyond the
scope of the study; however, effects on force of contraction
were added. We interpret that the increase in force of contrac-
tion with the profound elevation of plateau phase by XEN-
D0101, especially in SR which indirectly enhances Ca2+
entry,18 and an inhibitory effect on Ca2+ release seems unlikely.
Although a very high number of ECGs were analyzed in
this XEN-D0101 clinical study to provide excellent assay
sensitivity for detecting drug-related changes in the QTc
interval, this particular study was not performed according to
ICH E14 regulatory guidance. In particular, a positive phar-
macological control known to prolong the heart rate–corrected
QTc interval to an expected level was not included and ECG
monitoring covering the pharmacokinetic proﬁle of both the
parent compound and the metabolites was not performed.
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